Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphomas? experimental drug brincidofovir enters global trial

NCT ID NCT06761677

Terminated Disease control Sponsor: SymBio Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 02, 2026 · Last updated May 17, 2026 · Updated 24 times

Summary

This study tests an experimental drug called brincidofovir given through a vein for people with lymphoma that has returned or not responded to prior therapy. The trial has two parts: first, finding the safest dose in up to 18 participants with various lymphomas, then testing that dose in 25 people with a specific type called extranodal NK/T-cell lymphoma. The goal is to see if the drug is safe and can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA INCLUDING ENKL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer Institute Hospital Of JFCR

    Kōtoku, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Mie University Hospital

    Tsu, Japan

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Okayama University Hospital

    Okayama, Japan

  • Queen Mary Hospital

    Hong Kong, China

  • Tokyo Metropolitan Komagome Hospital

    Bunkyō City, Japan

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY LYMPHOMA INCLUDING ENKL